Get the Stockscreener App
10.31
7.70%
-0.86
Upstream Bio Inc stock is traded at $10.31, with a volume of 521.11K.
It is down -7.70% in the last 24 hours and up +19.33% over the past month.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
See More
Previous Close:
$11.17
Open:
$11.02
24h Volume:
521.11K
Relative Volume:
1.59
Market Cap:
$623.47M
Revenue:
$2.22M
Net Income/Loss:
$-40.51M
P/E Ratio:
-8.0252
EPS:
-1.2847
Net Cash Flow:
$-46.53M
1W Performance:
-11.04%
1M Performance:
+19.33%
6M Performance:
-47.48%
1Y Performance:
+0.00%
1-Day Range:
$10.10
$11.31
1-Week Range:
$10.10
$12.10
52-Week Range:
$5.14
$29.46
Upstream Bio Inc Stock (UPB) Company Profile
Name
Upstream Bio Inc
Sector
Industry
Phone
781-208-2466
Address
890 WINTER STREET, SUITE 200, WALTHAM
Compare UPB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
10.31 | 623.47M | 2.22M | -40.51M | -46.53M | -1.2847 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | Piper Sandler | Overweight |
| Nov-05-24 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Initiated | William Blair | Outperform |
Upstream Bio Inc Stock (UPB) Latest News
Upstream Bio, Inc.’s Verekitug: A Promising Contender in the TSLPR Antibody Space - TipRanks
Upstream Bio Stock Gets A Boost As New Lung Inflammation Drug Shows Higher Potency - Asianet Newsable
Upstream Bio announces presentation of data on verekitug’s TSLP receptor - TipRanks
Translational Data Illustrate a Mechanism of Greater - GlobeNewswire
Upstream Bio Presents Pharmacology Modeling Data Supporting Verekitug's Potency over Tezepelumab at EAACI Congress - Nasdaq
Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor - GlobeNewswire Inc.
Bank of America Corp DE Takes Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Upstream Bio Holds 2025 Annual Stockholders Meeting - TipRanks
Better Energy Stock: TotalEnergies vs. Chevron - The Globe and Mail
Upstream Bio (NASDAQ:UPB) Raised to Hold at Wall Street Zen - Defense World
Nuveen Asset Management LLC Takes Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Upstream Bio, Inc. to Present TSLP Receptor Targeting Data for Verekitug at EAACI Congress 2025 - Nasdaq
Upstream Bio to Present Mechanistic Insights into - GlobeNewswire
Breakthrough: Upstream Bio's Verekitug Demonstrates Enhanced Potency Over Current Asthma Treatments - Stock Titan
Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - The Manila Times
Upstream Bio to Reveal Latest Inflammatory Disease Treatment Progress at Major Goldman Sachs Conference - Stock Titan
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases New Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Deutsche Bank AG Invests $244,000 in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
An Extremely Profitable Business Plans to Go Public. What Investors Need to Know. - The Globe and Mail
Northern Trust Corp Makes New Investment in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Jane Street Group LLC Takes Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Upstream Bio names new chief technology officer By Investing.com - Investing.com South Africa
Upstream Bio names new chief technology officer - Investing.com Australia
Upstream Bio Appoints Stacy Price as Chief Technology Officer - GlobeNewswire
Upstream Bio, Inc. Appoints Stacy Price as Chief Technology Officer to Lead Expansion of Technical Operations - Nasdaq
Upstream Bio Strengthens Leadership Team: Former Invivyd Executive Takes CTO Role for Critical Clinical Program - Stock Titan
Upstream Bio Leads Life Sciences IPOs With Upsized Listing - MSN
Tower Research Capital LLC TRC Takes Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Is Upstream Bio Inc (NASDAQ: UPB) A Good Investment Now? - Stocksregister
Wells Fargo & Company MN Invests $149,000 in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
27,017 Shares in Upstream Bio, Inc. (NASDAQ:UPB) Acquired by Barclays PLC - Defense World
MetLife Investment Management LLC Invests $181,000 in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Brokers Offer Predictions for Upstream Bio Q2 Earnings - Defense World
Metric Analysis: Upstream Bio Inc (UPB)’s Key Ratios in the Limelight - DWinneX
Upstream Bio Advances Verekitug in Clinical Trials - TipRanks
Upstream Bio, Inc.: Strong Buy Rating Driven by Promising Drug Progress and Solid Financial Position - TipRanks
Upstream Bio reports Q1 revenue $566k, consensus $326.25k - TipRanks
Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs - GlobeNewswire
Transpire Bio Announces R&D and Manufacturing Expansion - The Manila Times
Upstream Bio Fast-Tracks Clinical Trials: Key Data Coming Earlier for Revolutionary Respiratory Drug - Stock Titan
Invesco Ltd. Buys Shares of 15,602 Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
1,734 Shares in Upstream Bio, Inc. (NASDAQ:UPB) Purchased by Legal & General Group Plc - Defense World
Gold Price and Miners Look Less Shiny as Global Trade Tensions Begin to Ease - The Globe and Mail
JPMorgan Chase & Co. Acquires Shares of 47,792 Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
LPL Financial LLC Cuts Stake in Invesco FTSE RAFI Developed Markets ex-U.S. Small-Mid ETF (NYSEARCA:PDN) - Defense World
Geode Capital Management LLC Purchases New Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Upstream Bio Inc’s Banking’s 100-Day Moving Average at 11.87: Will the Stock Break Through? - investchronicle.com
Medical Properties Trust Inc (MPW) Stock: Navigating a Year of Volatility - investchronicle.com
CytomX Therapeutics Inc’s Shares Reel: -10.73% Quarterly Revenue Decline Amid 60.07M Market Cap - investchronicle.com
Philip Morris International Inc (PM) Stock: Uncovering 52-Week Market Trends - investchronicle.com
Upstream Bio: Verekitug, A Longer-Acting Dupixent?Key Data Is Imminent - Seeking Alpha
Upstream Bio Inc Stock (UPB) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):